Looks at how treatments work for two forms of arthritis
Reviews medical records and patient surveys on drugs for spine and psoriatic arthritis.
Plain-language title generated from the registry record
Registry title: Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor
Key facts
- Where
- Bath, United KingdomSee the site
Where in United Kingdom
- Royal National Hospital for Rheumatic DiseasesBath, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Adelphi Real World
- Trial code
- NCT07166315
- Record updated
- 27 October 2026
- Original description
This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.Read full original descriptionShow less
Clinical Characteristics, Treatment Patterns and Outcomes in Patients With axSpA and PsA Following Initiation of Bimekizumab, Risankizumab, Guselkumab, Upadacitinib or a TNF Inhibitor
This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.
Inclusion: Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA); Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their axSpA or PsA; Participant is aged 18 years or older at enrolment.
Exclusion: -Participation in a clinical trial at enrolment.